APA (7th ed.) Citation

Chen, M., Lee, I., Chen, M., Hou, M., Tsai, C., & Huang, Y. (2021). Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Annals of the rheumatic diseases, 80(11), 1393-1399. https://doi.org/10.1136/annrheumdis-2021-220774

Chicago Style (17th ed.) Citation

Chen, Ming-Han, I-Cheng Lee, Ming-Huang Chen, Ming-Chih Hou, Chang-Youh Tsai, and Yi-Hsiang Huang. "Abatacept Is Second to Rituximab at Risk of HBsAg Reverse Seroconversion in Patients with Rheumatic Disease." Annals of the Rheumatic Diseases 80, no. 11 (2021): 1393-1399. https://doi.org/10.1136/annrheumdis-2021-220774.

MLA (9th ed.) Citation

Chen, Ming-Han, et al. "Abatacept Is Second to Rituximab at Risk of HBsAg Reverse Seroconversion in Patients with Rheumatic Disease." Annals of the Rheumatic Diseases, vol. 80, no. 11, 2021, pp. 1393-1399, https://doi.org/10.1136/annrheumdis-2021-220774.